Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts give DAWN a consensus rating of Hold from 10 firms (1 sell, 8 hold, 1 buy) with an average 12‑month price target of $23.29.
• Day One reported an EPS miss of ($0.21) vs. ($0.17) estimate while beating revenue at $53.72M; the company remains unprofitable with negative margins and a $2.22B market cap as the stock trades near its 1‑year high (~$21.47).
• Senior insiders (including the CFO and CEO) sold shares in February—36,461 shares sold in the last quarter—while institutional investors hold about 87.95% of the stock.

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have received a consensus rating of "Hold" from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $23.2857.

Several research firms have weighed in on DAWN. TD Cowen downgraded Day One Biopharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, March 6th. Zacks Research downgraded Day One Biopharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 25th. HC Wainwright reiterated a "neutral" rating and set a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 10th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $21.50 price target (down from $27.00) on shares of Day One Biopharmaceuticals in a research note on Wednesday, March 11th. Finally, JonesTrading downgraded Day One Biopharmaceuticals from a "buy" rating to a "hold" rating and boosted their price target for the company from $20.00 to $21.50 in a research note on Friday, March 6th.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $21.47 on Friday. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $21.48. The stock's fifty day moving average price is $16.57 and its 200 day moving average price is $11.54. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -20.84 and a beta of -1.74.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million for the quarter, compared to analysts' expectations of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. As a group, equities research analysts anticipate that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 6,065 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the sale, the chief financial officer owned 312,025 shares in the company, valued at approximately $3,619,490. The trade was a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeremy Bender sold 15,459 shares of the business's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $179,324.40. Following the sale, the chief executive officer owned 204,603 shares in the company, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of DAWN. Federated Hermes Inc. acquired a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at about $39,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Day One Biopharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company's stock valued at $46,000 after buying an additional 1,029 shares during the period. Quarry LP acquired a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at about $49,000. Prudential Financial Inc. acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at about $69,000. Finally, CWM LLC lifted its holdings in shares of Day One Biopharmaceuticals by 32.4% in the 4th quarter. CWM LLC now owns 8,373 shares of the company's stock valued at $78,000 after buying an additional 2,051 shares during the period. Institutional investors and hedge funds own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company's pipeline includes several small-molecule candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.